Nektar Therapeutics 1 article

Nektar Therapeutics occupies a defined biopharma niche through rezpegaldesleukin regulatory T-cell agonism and atopic dermatitis immunotherapy, consistent with its role as a biopharmaceutical company. For Nektar Therapeutics, immune tolerance restoration and cytokine-based biologic therapeutics broaden the research base, while PEGylated drug engineering experience adds a specific target, pathway, delivery method or disease context. The corporate tag for Nektar Therapeutics includes autoimmune inflammatory disease development as context, while individual drugs and mechanisms are modeled independently.